Ruben A Mesa (Ruben Mesa)

Publication Activity (10 Years)

Years Active: 2019-2024
Publications (10 Years): 58

Top Topics

Sickle Cell Disease

Randomized Controlled Trial

Prognostic Factors

Chronic Myeloid Leukemia

Top Venues

British journal of haematology

Cancer research communications

JMIR formative research

This page only lists publications with an associated author ORCID identifier.

Publications

Aaron T Gerds, Claire Harrison, Jean-Jacques Kiladjian, Ruben A Mesa, Alessandro Maria Maria Vannucchi, Rami S Komrokji, Prithviraj Bose, Marina Kremyanskaya, Adam J Mead, Jason Gotlib, Shelonitda Rose, Fabian Sanabria, Niloufar Marsousi, Ana Carolina Giuseppi, Huijing Jiang, Jeanne M Palmer, Kelly McCaul, Vincent Ribrag, Francesco Passamonti
Safety and efficacy of luspatercept for the treatment of anemia in patients with myelofibrosis. Blood advances 8 (17) (2024)
Aaron T Gerds, Claire Harrison, Jean-Jacques Kiladjian, Ruben A Mesa, Alessandro Maria Maria Vannucchi, Rami S Komrokji, Prithviraj Bose, Marina Kremyanskaya, Adam J Mead, Jason Gotlib, Shelonitda Rose, Fabian Sanabria, Niloufar Marsousi, Ana Carolina Giuseppi, Huijing Jiang, Jeanne M Palmer, Kelly McCaul, Vincent Ribrag, Francesco Passamonti
Safety and efficacy of luspatercept for the treatment of anemia in patients with myelofibrosis. Blood advances 8 (17) (2024)
Hannah Goulart, Lucia Masarova, Ruben A Mesa, Claire N Harrison, Jean-Jacques Kiladjian, Naveen Pemmaraju
Myeloproliferative neoplasms in the adolescent and young adult population: A comprehensive review of the literature. British journal of haematology 205 (1) (2024)
Laura F Mendez Luque, Julio Avelar-Barragan, Hellen Nguyen, Jenny Nguyen, Eli M Soyfer, Jiarui Liu, Jane H Chen, Nitya Mehrotra, Xin Helen Huang, Heidi E Kosiorek, Amylou C Dueck, Alexander S Himstead, Elena S Heide, Melinda Lem, Kenza El Alaoui, Eduard Mas, Robyn M Scherber, Ruben A Mesa, Katrine L Whiteson, Andrew O Odegaard, Angela G Fleischman
The NUTRIENT Trial (NUTRitional Intervention among myEloproliferative Neoplasms): Results from a Randomized Phase I Pilot Study for Feasibility and Adherence. Cancer research communications (2024)
Laura F Mendez Luque, Julio Avelar-Barragan, Hellen Nguyen, Jenny Nguyen, Eli M Soyfer, Jiarui Liu, Jane H Chen, Nitya Mehrotra, Xin Helen Huang, Heidi E Kosiorek, Amylou C Dueck, Alexander S Himstead, Elena S Heide, Melinda Lem, Kenza El Alaoui, Eduard Mas, Robyn M Scherber, Ruben A Mesa, Katrine L Whiteson, Andrew O Odegaard, Angela G Fleischman
The NUTRIENT Trial (NUTRitional Intervention among myEloproliferative Neoplasms): Results from a Randomized Phase I Pilot Study for Feasibility and Adherence. Cancer research communications (2024)
Aaron T Gerds, Claire N Harrison, Jean-Jacques Kiladjian, Ruben A Mesa, Alessandro Maria Maria Vannucchi, Rami S Komrokji, Prithviraj Bose, Marina Kremyanskaya, Adam Mead, Jason Gotlib, Shelonitda Rose, Fabian Sanabria, Niloufar Marsousi, Ana Carolina Giuseppi, Huijing Jiang, Jeanne M Palmer, Kelly McCaul, Vincent Ribrag, Francesco Passamonti
Safety and efficacy of luspatercept for the treatment of anemia in patients with myelofibrosis. Blood advances (2024)
Hannah Goulart, Lucia Masarova, Ruben A Mesa, Claire N Harrison, Jean-Jacques Kiladjian, Naveen Pemmaraju
Myeloproliferative neoplasms in the adolescent and young adult population: A comprehensive review of the literature. British journal of haematology (2024)
Hannah Goulart, Lucia Masarova, Ruben A Mesa, Claire N Harrison, Jean-Jacques Kiladjian, Naveen Pemmaraju
Myeloproliferative neoplasms in the adolescent and young adult population: A comprehensive review of the literature. British journal of haematology 205 (1) (2024)
Ayalew Tefferi, Giovanni Barosi, Francesco Passamonti, Juan Carlos Carlos Hernández-Boluda, Prithviraj Bose, Konstanze Döhner, Martin Ellis, Naseema Gangat, Jacqueline S Garcia, Heinz Gisslinger, Jason Gotlib, Paola Guglielmelli, Vikas K Gupta, Claire N Harrison, Elizabeth O Hexner, Gabriela S Hobbs, Jean-Jacques Kiladjian, Steffen Koschmieder, Nicolaus M Kröger, Andrew T Kuykendall, Giuseppe Gaetano Loscocco, John O Mascarenhas, Lucia Masarova, Ruben A Mesa, Barbara Mora, Olatoyosi Odenike, Stephen T Oh, Animesh D Pardanani, Anand Ashwin Patel, Naveen Pemmaraju, Alessandro Rambaldi, Raajit K Rampal, Shireen Sirhan, Natasha Szuber, Moshe Talpaz, Pankit Vachhani, Alessandro M Vannucchi, Tiziano Barbui
Proposals for Revised International Working Group-European LeukemiaNet Criteria for Anemia Response in Myelofibrosis. Blood (2024)
Laura F Mendez Luque, Julio Avelar-Barragan, Hellen Nguyen, Jenny Nguyen, Eli M Soyfer, Jiarui Liu, Jane H Chen, Nitya Mehrotra, Xin Helen Huang, Heidi E Kosiorek, Amylou C Dueck, Alexander S Himstead, Elena S Heide, Melinda Lem, Kenza El Alaoui, Eduard Mas, Robyn M Scherber, Ruben A Mesa, Katrine L Whiteson, Andrew O Odegaard, Angela G Fleischman
The NUTRIENT Trial (NUTRitional Intervention among myEloproliferative Neoplasms): Results from a Randomized Phase I Pilot Study for Feasibility and Adherence. Cancer research communications 4 (3) (2024)
Hannah Goulart, Lucia Masarova, Ruben A Mesa, Claire N Harrison, Jean-Jacques Kiladjian, Naveen Pemmaraju
Myeloproliferative neoplasms in the adolescent and young adult population: A comprehensive review of the literature. British journal of haematology 205 (1) (2024)
Laura F Mendez Luque, Julio Avelar-Barragan, Hellen Nguyen, Jenny Nguyen, Eli M Soyfer, Jiarui Liu, Jane H Chen, Nitya Mehrotra, Xin Helen Huang, Heidi E Kosiorek, Amylou C Dueck, Alexander S Himstead, Elena S Heide, Melinda Lem, Kenza El Alaoui, Eduard Mas, Robyn M Scherber, Ruben A Mesa, Katrine L Whiteson, Andrew O Odegaard, Angela G Fleischman
The NUTRIENT Trial (NUTRitional Intervention among myEloproliferative Neoplasms): Results from a Randomized Phase I Pilot Study for Feasibility and Adherence. Cancer research communications (2024)
Lisa R Rodriguez, Nicole J Gormley, Ruixiao Lu, Anup K Amatya, George D Demetri, Keith T Flaherty, Ruben A Mesa, Richard Pazdur, Mikkael A Sekeres, Minghua Shan, Steven Snapinn, Marc R Theoret, Rukiya Umoja, Jonathon Vallejo, Nicholas J H Warren, Qing Xu, Kenneth C Anderson
Improving Collection and Analysis of Overall Survival Data. Clinical cancer research : an official journal of the American Association for Cancer Research (2024)
Hannah Goulart, Lucia Masarova, Ruben A Mesa, Claire N Harrison, Jean-Jacques Kiladjian, Naveen Pemmaraju
Myeloproliferative neoplasms in the adolescent and young adult population: A comprehensive review of the literature. British journal of haematology (2024)
Laura F Mendez Luque, Julio Avelar-Barragan, Hellen Nguyen, Jenny Nguyen, Eli M Soyfer, Jiarui Liu, Jane H Chen, Nitya Mehrotra, Xin Helen Huang, Heidi E Kosiorek, Amylou C Dueck, Alexander S Himstead, Elena S Heide, Melinda Lem, Kenza El Alaoui, Eduard Mas, Robyn M Scherber, Ruben A Mesa, Katrine L Whiteson, Andrew O Odegaard, Angela G Fleischman
The NUTRIENT Trial (NUTRitional Intervention among myEloproliferative Neoplasms): Results from a Randomized Phase I Pilot Study for Feasibility and Adherence. Cancer research communications 4 (3) (2024)
Abdulraheem Yacoub, Ruben A Mesa, Stephen T Oh
Long-Term Hematologic Improvement in a Patient With Cytopenic Myelofibrosis Treated With Pacritinib. JCO precision oncology 7 (2023)
Carlos L Arteaga, John L Cleveland, Margaret Foti, Ruben A Mesa, Louis M Weiner, Cheryl L Willman, David A Tuveson
AACR Cancer Centers Alliance: Fostering Collaboration and Innovation to Advance Lifesaving Scientific Discoveries for Patients. Molecular cancer research : MCR (2023)
Claire N Harrison, Jyoti Nangalia, Rebecca Boucher, Aimee Jackson, Christina Yap, Jennifer O'Sullivan, Sonia Fox, Isaak Ailts, Amylou C Dueck, Holly L Geyer, Ruben A Mesa, William G Dunn, Eugene Nadezhdin, Natalia Curto-Garcia, Anna Green, Bridget Wilkins, Jason Coppell, John Laurie, Mamta Garg, Joanne Ewing, Stephen Knapper, Josephine Crowe, Frederick Chen, Ioannis Koutsavlis, Anna Godfrey, Siamak Arami, Mark Drummond, Jennifer L Byrne, Fiona Clark, Carolyn Mead-Harvey, Elizabeth Joanna Baxter, Mary Frances Frances McMullin, Adam J Mead
Ruxolitinib Versus Best Available Therapy for Polycythemia Vera Intolerant or Resistant to Hydroxycarbamide in a Randomized Trial. Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2023)
Carlos L Arteaga, John L Cleveland, Margaret Foti, Ruben A Mesa, Louis M Weiner, Cheryl L Willman, David A Tuveson
AACR Cancer Centers Alliance: Fostering Collaboration and Innovation to Advance Lifesaving Scientific Discoveries for Patients. Cancer discovery (2023)
Srdan Verstovsek, Jean-Jacques Kiladjian, Alessandro M Vannucchi, Ruben A Mesa, Peg Squier, J E Hamer-Maansson, Claire Harrison
Early intervention in myelofibrosis and impact on outcomes: A pooled analysis of the COMFORT-I and COMFORT-II studies. Cancer (2023)
Carlos L Arteaga, John L Cleveland, Margaret Foti, Ruben A Mesa, Louis M Weiner, Cheryl L Willman, David A Tuveson
AACR Cancer Centers Alliance: Fostering Collaboration and Innovation to Advance Lifesaving Scientific Discoveries for Patients. Cancer prevention research (Philadelphia, Pa.) (2023)
Carlos L Arteaga, John L Cleveland, Margaret Foti, Ruben A Mesa, Louis M Weiner, Cheryl L Willman, David A Tuveson
AACR Cancer Centers Alliance: Fostering Collaboration and Innovation to Advance Lifesaving Scientific Discoveries for Patients. Blood cancer discovery (2023)
Carlos L Arteaga, John L Cleveland, Margaret Foti, Ruben A Mesa, Louis M Weiner, Cheryl L Willman, David A Tuveson
AACR Cancer Centers Alliance: Fostering Collaboration and Innovation to Advance Lifesaving Scientific Discoveries for Patients. Molecular cancer therapeutics (2023)
Carlos L Arteaga, John L Cleveland, Margaret Foti, Ruben A Mesa, Louis M Weiner, Cheryl L Willman, David A Tuveson
AACR Cancer Centers Alliance: Fostering Collaboration and Innovation to Advance Lifesaving Scientific Discoveries for Patients. Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology (2023)
John O Mascarenhas, Anna Rita Migliaccio, Heidi E Kosiorek, Rupali Bhave, Jeanne M Palmer, Andrew T Kuykendall, Ruben A Mesa, Raajit K Rampal, Aaron T Gerds, Abdulraheem Yacoub, Kristen Pettit, Moshe Talpaz, Rami S Komrokji, Marina Kremyanskaya, Agapito Gonzalez, Frank Fabris, Kathryn Johnson, Mikaela Dougherty, Erin M McGovern, Juan Esteban Arango Ossa, Dylan Domenico, Noushin Farnoud, Rona Singer Weinberg, Amy Kong, Vesna Najfeld, Alessandro Maria Maria Vannucchi, Francesca Arciprete, Maria Zingariello, Mario Falchi, Mohamed E Salama, Carolyn Mead-Harvey, Amylou C Dueck, Lilian Varricchio, Ronald Hoffman
A Phase 1b trial of AVID200, a TGFβ 1/3 trap, in patients with myelofibrosis. Clinical cancer research : an official journal of the American Association for Cancer Research (2023)
Carlos L Arteaga, John L Cleveland, Margaret Foti, Ruben A Mesa, Louis M Weiner, Cheryl L Willman, David A Tuveson
AACR Cancer Centers Alliance: Fostering Collaboration and Innovation to Advance Lifesaving Scientific Discoveries for Patients. Clinical cancer research : an official journal of the American Association for Cancer Research (2023)
Ruben A Mesa, Stacie Hudgens, Lysbeth Floden, Claire N Harrison, Jeanne Palmer, Vikas Gupta, Donal P McLornan, Mary F McMullin, Jean-Jaques Kiladjian, Lynda Foltz, Uwe Platzbecker, M Laura Fox, Adam J Mead, David M Ross, Stephen T Oh, Andrew Perkins, Michael F Leahy, Samineh Deheshi, Rafe Donahue, Barbara J Klencke, Srdan Verstovsek
Symptomatic benefit of momelotinib in patients with myelofibrosis: Results from the SIMPLIFY phase III studies. Cancer medicine (2023)
Carlos L Arteaga, John L Cleveland, Margaret Foti, Ruben A Mesa, Louis M Weiner, Cheryl L Willman, David A Tuveson
AACR Cancer Centers Alliance: Fostering Collaboration and Innovation to Advance Lifesaving Scientific Discoveries for Patients. Cancer immunology research (2023)
Luis F Gonzalez-Mosquera, Bernard Moscoso, Pool Tobar, Diana Cardenas-Maldonado, Alida I Podrumar, Ruben A Mesa, John A Cuenca
Sepsis-Related Outcomes of Patients with Philadelphia-Negative Myeloproliferative Neoplasms. Cancer investigation (2023)
Lai Yee Orbell, Nouf Abutheraa, Andrew S Duncombe, Mary Frances McMullin, Ruben A Mesa, Charlene M McShane, Glen James, Lesley Ann Anderson
The JAK2 V617F mutation and the role of therapeutic agents in alleviating myeloproliferative neoplasm symptom burden. EJHaem 4 (4) (2023)
Tamara Kay Moyo, Ashwin Kishtagari, Matthew Villaume, Brandon J McMahon, Sanjay R Mohan, Tess Stopczynski, Sheau-Chiann Chen, Run Fan, Yuankai Huo, Hyeonsoo Moon, Yucheng Tang, Cosmin A Bejan, Merrida Childress, Ingrid A Anderson, Kyle Rawling, Rhea M Simons, Ashley Moncrief, Rebekah Caza, Laura Dugger, Aunshka Collins, Channing V Dudley, Paul Brent Ferrell, Michael T Byrne, Stephen A Strickland, Gregory D Ayers, Bennett A Landman, Emily F Mason, Ruben A Mesa, Jeanne M Palmer, Laura C Michaelis, Michael R Savona
PI3K Inhibition Restores and Amplifies Response to Ruxolitinib in patients with Myelofibrosis. Clinical cancer research : an official journal of the American Association for Cancer Research (2023)
Carlos L Arteaga, John L Cleveland, Margaret Foti, Ruben A Mesa, Louis M Weiner, Cheryl L Willman, David A Tuveson
AACR Cancer Centers Alliance: Fostering Collaboration and Innovation to Advance Lifesaving Scientific Discoveries for Patients. Cancer research (2023)
Abdulraheem Yacoub, Ruben A Mesa, Stephen T Oh
Long-Term Hematologic Improvement in a Patient With Cytopenic Myelofibrosis Treated With Pacritinib. JCO precision oncology 7 (2023)
Raoul Tibes, Heidi E Kosiorek, Amylou C Dueck, Jeanne M Palmer, Lisa Sproat, James Bogenberger, Shahrukh K. Hashmi, Ruben A Mesa, William Hogan, Mark R Litzow, Aref A Al-Kali
Phase 1/1b study of azacitidine and hedgehog pathway inhibitor sonidegib in patients with myeloid neoplasms. Cancer (2023)
Abdulraheem Yacoub, Ruben A Mesa, Stephen T Oh
Long-Term Hematologic Improvement in a Patient With Cytopenic Myelofibrosis Treated With Pacritinib. JCO precision oncology 7 (2023)
Heidi E Kosiorek, Robyn M Scherber, Holly L Geyer, Srdan Verstovsek, Blake T Langlais, Gina L Mazza, Jason Gotlib, Vikas K Gupta, Leslie J Padrnos, Jeanne M Palmer, Angela Fleischman, Ruben A Mesa, Amylou C Dueck
Quality of life independently predicts overall survival in myelofibrosis: Key insights from the COntrolled MyeloFibrosis Study with ORal Janus kinase inhibitor Treatment (COMFORT)-I study. British journal of haematology 198 (6) (2022)
Claire N Harrison, Nicolaas Schaap, Alessandro Maria Maria Vannucchi, Jean-Jacques Kiladjian, Francesco Passamonti, Sonja Zweegman, Moshe Talpaz, Srdan Verstovsek, Shelonitda Rose, Jun Zhang, Oumar Sy, Ruben A Mesa
Safety and efficacy of fedratinib, a selective oral inhibitor of Janus kinase-2 (JAK2), in patients with myelofibrosis and low pretreatment platelet counts. British journal of haematology 198 (2) (2022)
Jennifer L Huberty, Nishat Bhuiyan, Taylor L Neher, Lynda Joeman, Ruben A Mesa, Linda K Larkey
Leveraging a Consumer-Based Product to Develop a Cancer-Specific Mobile Meditation App: Prototype Development Study. JMIR formative research 6 (1) (2022)
Ruben A Mesa, Claire Harrison, Stephen T Oh, Aaron T Gerds, Vikas K Gupta, John Catalano, Francisco Cervantes, Timothy Devos, Marek Hus, Jean-Jacques Kiladjian, Ewa Lech-Maranda, Donal P McLornan, Alessandro M Vannucchi, Uwe Platzbecker, Mei Huang, Bryan Strouse, Barbara J Klencke, Srdan Verstovsek
Overall survival in the SIMPLIFY-1 and SIMPLIFY-2 phase 3 trials of momelotinib in patients with myelofibrosis. Leukemia 36 (9) (2022)
Ruben A Mesa, Stephen T Oh, Aaron T Gerds, Vikas Gupta, John Catalano, Francisco Cervantes, Timothy Devos, Marek Hus, Jean-Jacques Kiladjian, Ewa Lech-Maranda, Donal McLornan, Jeanne Palmer, Uwe Platzbecker, Jacek Treliński, Kazuya Shimoda, Rafe Donahue, Koenraad D'Hollander, Mark Kowalski, Srdan Verstovsek
Momelotinib reduces transfusion requirements in patients with myelofibrosis. Leukemia & lymphoma 63 (7) (2022)
John Soper, Islam Sadek, Alyson Urniasz-Lippel, Deborah Norton, Marina Ness, Ruben A Mesa
Patient and Caregiver Insights into the Disease Burden of Myelodysplastic Syndrome. Patient related outcome measures 13 (2022)
Hninyee Win, Samantha Russell, Betsy C Wertheim, Victoria Maizes, Robert L Crocker, Audrey J Brooks, Ruben A Mesa, Jennifer L Huberty, Holly L Geyer, Ryan Eckert, Ashley Larsen, Krisstina Gowin
Mobile App Intervention on Reducing the Myeloproliferative Neoplasm Symptom Burden: Pilot Feasibility and Acceptability Study. JMIR formative research 6 (3) (2022)
Claire N Harrison, Jacqueline S Garcia, Tim C P Somervaille, James M Foran, Srdan Verstovsek, Catriona Jamieson, Ruben A Mesa, Ellen K Ritchie, Srinivas K Tantravahi, Pankit Vachhani, Casey L O'Connell, Rami S Komrokji, Jason Harb, Jessica E Hutti, Leanne Holes, Abdullah A Masud, Silpa Nuthalapati, Jalaja Potluri, Naveen Pemmaraju
Addition of Navitoclax to Ongoing Ruxolitinib Therapy for Patients With Myelofibrosis With Progression or Suboptimal Response: Phase II Safety and Efficacy. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 40 (15) (2022)
Jennifer L Huberty, Nishat Bhuiyan, Megan Elizabeth Puzia, Lynda Joeman, Linda K Larkey, Ruben A Mesa
Meditation Mobile App Developed for Patients With and Survivors of Cancer: Feasibility Randomized Controlled Trial. JMIR cancer 8 (4) (2022)
Douglas Tremblay, Ruben A Mesa
Momelotinib for the treatment of myelofibrosis with anemia. Future oncology (London, England) 18 (20) (2022)
Naveen Pemmaraju, Srdan Verstovsek, Ruben A Mesa, Vikas Gupta, Jacqueline S Garcia, Joseph Michael Scandura, Stephen T Oh, Francesco Passamonti, Konstanze Döhner, Adam J Mead
Defining disease modification in myelofibrosis in the era of targeted therapy. Cancer 128 (13) (2022)
Douglas Tremblay, Ruben A Mesa
Novel treatments for myelofibrosis: beyond JAK inhibitors. International journal of hematology 115 (5) (2022)
Ellen K Ritchie, Anas Al-Janadi, Craig Kessler, Robyn Scherber, Tricia Kalafut, Haobo Ren, Ruben A Mesa
Patient-reported outcomes of patients with myelofibrosis or essential thrombocythemia enrolled in the MOST study. Leukemia & lymphoma (2022)
Claire N Harrison, Vikas K Gupta, Aaron T Gerds, Raajit K Rampal, Srdan Verstovsek, Moshe Talpaz, Jean-Jacques Kiladjian, Ruben A Mesa, Andrew T Kuykendall, Alessandro Maria Maria Vannucchi, Francesca Palandri, Sebastian Grosicki, Timothy Devos, Eric Jourdan, Marielle J Wondergem, Haifa Kathrin Al-Ali, Veronika Buxhofer-Ausch, Alberto Álvarez-Larrán, Andrea Patriarca, Marina Kremyanskaya, Adam J Mead, Sanjay Akhani, Yuri Sheikine, Gozde Colak, John O Mascarenhas
Phase III MANIFEST-2: pelabresib + ruxolitinib vs placebo + ruxolitinib in JAK inhibitor treatment-naive myelofibrosis. Future oncology (London, England) 18 (27) (2022)
John O Mascarenhas, Francesco Passamonti, Kate Burbury, Tarec Christoffer El-Galaly, Aaron T Gerds, Vikas K Gupta, Brian Higgins, Kathrin Wonde, Candice Jamois, Bruno Kovic, Ling-Yuh Huw, Sudhakar Katakam, Margherita Maffioli, Ruben A Mesa, Jeanne Palmer, Marta Bellini, David Morrall Ross, Alessandro Maria Maria Vannucchi, Abdulraheem Yacoub
The MDM2 antagonist idasanutlin in patients with polycythemia vera: results from a single-arm phase 2 study. Blood advances 6 (4) (2022)
Samuel M Rubinstein, Divaya Bhutani, Ryan C Lynch, Chih-Yuan Hsu, Yu Shyr, Shailesh Advani, Ruben A Mesa, Sanjay Mishra, Daniel P Mundt, Dimpy P Shah, R Alejandro Sica, Keith E Stockerl-Goldstein, Catherine S M Stratton, Matthias Weiss, Alicia Beeghly-Fadiel, Melissa K Accordino, Sarit E Assouline, Joy Awosika, Ziad Bakouny, Babar Bashir, Stephanie A Berg, Mehmet Asim Bilen, Cecilia A Castellano, Jacob C Cogan, Devendra Kc, Christopher R Friese, Shilpa Gupta, Daniel Hausrath, Clara Hwang, Nathalie A Johnson, Monika Joshi, Anup Kasi Loknath Kumar, Elizabeth J Klein, Vadim S Koshkin, Nicole M Kuderer, Daniel H Kwon, Chris Labaki, Tahir Latif, Eric K C Lau, Xuanyi Li, Gary H Lyman, Rana R McKay, Gayathri Nagaraj, Amanda Nizam, Taylor K Nonato, Adam J Olszewski, Hyma V Polimera, Andrew Jay Portuguese, Matthew M Puc, Pedram Razavi, Rachel Rosovski, Andrew L Schmidt, Sumit A Shah, Aditi Shastri, Christopher T Su, Pallawi Torka, Trisha Michel Wise-Draper, Leyre Zubiri, Jeremy L Warner, Michael A Thompson, null null
Patients Recently Treated for B-lymphoid Malignancies Show Increased Risk of Severe COVID-19. Blood cancer discovery 3 (3) (2022)
Jennifer L Huberty, Nishat Bhuiyan, Ryan Eckert, Linda K Larkey, Megan E Petrov, Michael Todd, Ruben A Mesa
Insomnia as an Unmet Need in Patients With Chronic Hematological Cancer: Protocol for a Randomized Controlled Trial Evaluating a Consumer-Based Meditation App for Treatment of Sleep Disturbance. JMIR research protocols 11 (7) (2022)
Prithviraj Bose, Ruben A Mesa
Novel strategies for challenging scenarios encountered in managing myelofibrosis. Leukemia & lymphoma (2021)
Srdan Verstovsek, Chih-Cheng Chen, Miklós Egyed, Martin Ellis, Maria Laura Fox, Yeow T Goh, Vikas K Gupta, Claire Harrison, Jean-Jacques Kiladjian, Mihaela C Lazaroiu, Adam J Mead, Donal McLornan, Mary Frances Frances McMullin, Stephen T Oh, Andrew Charles Perkins, Uwe Platzbecker, Christof Scheid, Alessandro Maria Maria Vannucchi, Sung-Soo Yoon, Mark M Kowalski, Ruben A Mesa
MOMENTUM: momelotinib vs danazol in patients with myelofibrosis previously treated with JAKi who are symptomatic and anemic. Future oncology (London, England) 17 (12) (2021)
Jennifer L Huberty, Ryan Eckert, Megan Elizabeth Puzia, Breanne Laird, Linda K Larkey, Ruben A Mesa
A Novel Educational Control Group Mobile App for Meditation Interventions: Single-Group Feasibility Trial. JMIR formative research 4 (7) (2020)
Ramon S Cancino, Zhaohui Su, Ruben A Mesa, Gail E Tomlinson, Jing Wang
The Impact of COVID-19 on Cancer Screening: Challenges and Opportunities. JMIR cancer 6 (2) (2020)
Jennifer L Huberty, Ryan Eckert, Linda K Larkey, Lynda Joeman, Ruben A Mesa
Experiences of Using a Consumer-Based Mobile Meditation App to Improve Fatigue in Myeloproliferative Patients: Qualitative Study. JMIR cancer 5 (2) (2019)
Jennifer L Huberty, Ryan Eckert, Linda K Larkey, Jonathan Kurka, Sue A Rodríguez De Jesús, Wonsuk Yoo, Ruben A Mesa
Smartphone-Based Meditation for Myeloproliferative Neoplasm Patients: Feasibility Study to Inform Future Trials. JMIR formative research 3 (2) (2019)